clarithromycin has been researched along with clopidogrel in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bodmer, M; Brecht, K; Bur, D; Krähenbühl, S; Tsakiris, DA; Zahno, A | 1 |
| Bae, SK; Lee, SS; Pan, W; Park, SE; Park, SJ; Shim, EJ; Shin, JG; Shon, JH; Yeo, CW; Zhou, HH | 1 |
| Bae, SK; Choi, JS; Kim, DH; Kim, HS; Pan, W; Shin, JG; Shinde, DD; Shon, JH; Yeo, CW | 1 |
| Bykov, K; Gagne, JJ; Glynn, RJ; Mittleman, MA; Schneeweiss, S | 1 |
| Ogawa, SI; Shimizu, M; Yamazaki, H | 1 |
2 review(s) available for clarithromycin and clopidogrel
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for clarithromycin and clopidogrel
| Article | Year |
|---|---|
Different effects of clopidogrel and clarithromycin on the enantioselective pharmacokinetics of sibutramine and its active metabolites in healthy subjects.
Topics: Adult; Appetite Depressants; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Clopidogrel; Cross-Over Studies; Cyclobutanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Genotype; Humans; Male; Microsomes; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Stereoisomerism; Ticlopidine; Young Adult | 2013 |
5 other study(ies) available for clarithromycin and clopidogrel
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Clarithromycin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Heptanoic Acids; Humans; In Vitro Techniques; Ketoconazole; Microsomes, Liver; Models, Molecular; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrroles; Recombinant Proteins; Simvastatin; Substrate Specificity; Ticlopidine | 2010 |
Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism.
Topics: Anti-Bacterial Agents; Appetite Depressants; Aryl Hydrocarbon Hydroxylases; Asian People; Clarithromycin; Clopidogrel; Cyclobutanes; Cytochrome P-450 CYP2B6; Humans; Male; Oxidoreductases, N-Demethylating; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Republic of Korea; Ticlopidine | 2013 |
The Case-Crossover Design for Drug-Drug Interactions: Considerations for Implementation.
Topics: Administrative Claims, Healthcare; Azithromycin; Clarithromycin; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Interactions; Electronic Health Records; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Implementation Science; Models, Statistical; Rhabdomyolysis; Risk Factors; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome | 2019 |
Modelled plasma concentrations of pemafibrate with co-administered typical cytochrome P450 inhibitors clopidogrel, fluconazole or clarithromycin predicted by physiologically based pharmacokinetic modelling in virtual populations.
Topics: Benzoxazoles; Butyrates; Clarithromycin; Clopidogrel; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Fluconazole; Humans; Liver; Pharmaceutical Preparations | 2020 |